A customer studies the labels on medicine at a drug store in Dandong, Liaoning province. [Chen Hao/China Daily]

BEIJING - The State Food and Drug Administration is set to launch a nationwide probe into the quality of essential drugs in a bid to protect people from problem medication.

The drugs being looked at are those deemed to satisfy the basic healthcare needs of the majority of the population.

The two-month examination will look closely at how drugs are produced and where their raw materials are sourced, said an online notice issued by the administration on Friday.

Drug authorities across the mainland will carry out on-site examinations at production facilities and report their findings to the administration before the end of June.

Currently, 2,822 companies are producing essential drugs on the mainland, official statistics show.

Through such campaigns, according to the notice, an effective working mechanism that ensures drug safety, particularly the safety of widely used essential drugs, is expected to be set up.

According to industry analysts, China's major problems with drug safety are in the areas of anti-infection drugs and traditional Chinese medicine.

In 2010, China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions, 8.4 percent more than in 2009, official statistics showed.

Out of that total, 109,991 were reports of new or severe adverse reactions, making for an increase of 16.2 percent year-on-year.

Drug safety incidents have hit the headlines. Hong Kong's Department of Health on Friday ordered the wholesaler of a proprietary Chinese medicine to recall from consumers a batch of Hua Tuo Brand Baoying Dan, known to be used by children for the treatment of generalized discomfort like restlessness at night or fever, according to a report of the Xinhua News Agency.

The action was called for after a sample was obtained by the department's inspectors and found to contain about two times the permitted level of mercury, it said. The case has been referred to the administration for further investigation.

Strengthening the supervision of essential drugs' production and quality to ensure safety is a working priority for the country's drug authorities, the notice said.

It also demanded effective measures be adopted to eliminate essential drugs' quality problems and remove any hidden risks.